1H-1,2,3-Triazole-5-carboxylic acid, 1-(2,6-dichlorophenyl)-4-(1-methylethyl)-, methyl ester | 1643862-37-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1H-1,2,3-Triazole-5-carboxylic acid, 1-(2,6-dichlorophenyl)-4-(1-methylethyl)-, methyl ester
• 英文别名: methyl 3-(2,6-dichlorophenyl)-5-propan-2-yltriazole-4-carboxylate
• CAS: 1643862-37-6
• 化学式: C₁₃H₁₃Cl₂N₃O₂
• 分子量: 314.171
• InChiKey: LIBMUTUWHVLNFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  57
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1H-1,2,3-Triazole-5-carboxylic acid, 1-(2,6-dichlorophenyl)-4-(1-methylethyl)-, methyl ester 在 偶氮二甲酸二异丙酯 、 二异丁基氢化铝 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成 3-(2-{2-chloro-4-[3-(2,6-dichloro-phenyl)-5-isopropyl-3H-[1,2,3]triazol-4-ylmethoxy]-phenyl}-vinyl)-benzoic acid methyl ester
  参考文献：
  名称：

  Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists

  摘要：

  The farnesoid X receptor (FXR) may play a crucial role in a number of metabolic diseases and, as such, could potentially serve as a target for the development of therapeutics as a treatment for those diseases. Previous work has described GW4064 as an FXR agonist with an interesting activity profile. This manuscript will describe the synthesis of novel analogs of GW4064 and the activity profile of those analogs. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.11.050
• 作为产物：
  描述：

  methyl 4-methylpent-2-ynoate 、 2-叠氮基-1,3-二氯苯 以 neat (no solvent) 为溶剂， 以30%的产率得到1H-1,2,3-Triazole-5-carboxylic acid, 1-(2,6-dichlorophenyl)-4-(1-methylethyl)-, methyl ester
  参考文献：
  名称：

  Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists

  摘要：

  The farnesoid X receptor (FXR) may play a crucial role in a number of metabolic diseases and, as such, could potentially serve as a target for the development of therapeutics as a treatment for those diseases. Previous work has described GW4064 as an FXR agonist with an interesting activity profile. This manuscript will describe the synthesis of novel analogs of GW4064 and the activity profile of those analogs. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.11.050

文献信息

• Tricyclic compounds and uses thereof in medicine
  申请人：Sunshine Lake Pharma Co., Ltd.

  公开号：US10183917B2

  公开（公告）日：2019-01-22

  The present invention relates to novel tricyclic compounds which can bind to FXR and act as modulators of the FXR, or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and the uses of the compounds for the treatment of diseases and/or conditions mediated by FXR. The invention further provides a pharmaceutical composition containing the compound disclosed herein and a method of treatment of diseases and/or conditions mediated by FXR comprising administering the compound or the pharmaceutical composition.

  本发明涉及能与FXR结合并作为FXR调节剂的新型三环化合物，或其立体异构体、几何异构体、同分异构体、N-氧化物、水合物、溶质、代谢物、药学上可接受的盐或原药，以及该化合物用于治疗由FXR介导的疾病和/或病症的用途。本发明进一步提供了一种含有本文公开的化合物的药物组合物，以及一种治疗由FXR介导的疾病和/或病症的方法，该方法包括施用该化合物或药物组合物。
• TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE
  申请人：Sunshine Lake Pharma Co., Ltd.

  公开号：EP3256468B1

  公开（公告）日：2020-04-08
• Novel heterocyclic scaffolds of GW4064 as farnesoid X receptor agonists
  作者：Terrence L. Smalley、Sharon Boggs、Justin A. Caravella、Lihong Chen、Katrina L. Creech、David N. Deaton、Istvan Kaldor、Derek J. Parks

  DOI：10.1016/j.bmcl.2014.11.050

  日期：2015.1

  The farnesoid X receptor (FXR) may play a crucial role in a number of metabolic diseases and, as such, could potentially serve as a target for the development of therapeutics as a treatment for those diseases. Previous work has described GW4064 as an FXR agonist with an interesting activity profile. This manuscript will describe the synthesis of novel analogs of GW4064 and the activity profile of those analogs. (C) 2014 Elsevier Ltd. All rights reserved.